| 000 | 01741 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515060630.0 | ||
| 264 | 0 | _c20070724 | |
| 008 | 200707s 0 0 eng d | ||
| 022 | _a0960-894X | ||
| 024 | 7 |
_a10.1016/j.bmcl.2007.01.112 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEary, C Todd | |
| 245 | 0 | 0 |
_aTetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry letters _cMay 2007 |
||
| 300 |
_a2608-13 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aChemistry, Pharmaceutical _xmethods |
| 650 | 0 | 4 |
_aCholesterol Ester Transfer Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCholesterol, HDL _xmetabolism |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aEsters _xchemistry |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydrogen-Ion Concentration |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 | _aMolecular Conformation |
| 650 | 0 | 4 |
_aQuinoxalines _xchemical synthesis |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aStereoisomerism |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 |
_aTetrazoles _xchemistry |
| 700 | 1 | _aJones, Zachary S | |
| 700 | 1 | _aGroneberg, Robert D | |
| 700 | 1 | _aBurgess, Laurence E | |
| 700 | 1 | _aMareska, David A | |
| 700 | 1 | _aDrew, Mark D | |
| 700 | 1 | _aBlake, James F | |
| 700 | 1 | _aLaird, Ellen R | |
| 700 | 1 | _aBalachari, Devan | |
| 700 | 1 | _aO'Sullivan, Michael | |
| 700 | 1 | _aAllen, Andrew | |
| 700 | 1 | _aMarsh, Vivienne | |
| 773 | 0 |
_tBioorganic & medicinal chemistry letters _gvol. 17 _gno. 9 _gp. 2608-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bmcl.2007.01.112 _zAvailable from publisher's website |
| 999 |
_c16889038 _d16889038 |
||